Triggering TLR signaling in vaccination
Toll-like receptors (TLRs) are a family of pattern-recognition receptors that are an important link between innate and adaptive immunity. Many established, as well as experimental, vaccines incorporate ligands for TLRs, not only to protect against infectious diseases but also in therapeutic immuniza...
Saved in:
| Published in | Trends in Immunology Vol. 27; no. 1; pp. 49 - 55 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
2006
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-4906 1471-4981 1365-2567 |
| DOI | 10.1016/j.it.2005.11.005 |
Cover
Loading…
| Abstract | Toll-like receptors (TLRs) are a family of pattern-recognition receptors that are an important link between innate and adaptive immunity. Many established, as well as experimental, vaccines incorporate ligands for TLRs, not only to protect against infectious diseases but also in therapeutic immunization against noninfectious diseases, such as cancer. We review the underlying mechanisms by which engagement of TLR signaling pathways might trigger an adaptive immune response after immunization. Although the engagement of TLR signaling pathways is a promising mechanism for boosting vaccine responses, questions of efficacy, feasibility and safety remain the subject of active investigation. |
|---|---|
| AbstractList | Toll-like receptors (TLRs) are a family of pattern-recognition receptors that are an important link between innate and adaptive immunity. Many established, as well as experimental, vaccines incorporate ligands for TLRs, not only to protect against infectious diseases but also in therapeutic immunization against noninfectious diseases, such as cancer. We review the underlying mechanisms by which engagement of TLR signaling pathways might trigger an adaptive immune response after immunization. Although the engagement of TLR signaling pathways is a promising mechanism for boosting vaccine responses, questions of efficacy, feasibility and safety remain the subject of active investigation. Toll-like receptors (TLRs) are a family of pattern-recognition receptors that are an important link between innate and adaptive immunity. Many established, as well as experimental, vaccines incorporate ligands for TLRs, not only to protect against infectious diseases but also in therapeutic immunization against noninfectious diseases, such as cancer. We review the underlying mechanisms by which engagement of TLR signaling pathways might trigger an adaptive immune response after immunization. Although the engagement of TLR signaling pathways is a promising mechanism for boosting vaccine responses, questions of efficacy, feasibility and safety remain the subject of active investigation.Toll-like receptors (TLRs) are a family of pattern-recognition receptors that are an important link between innate and adaptive immunity. Many established, as well as experimental, vaccines incorporate ligands for TLRs, not only to protect against infectious diseases but also in therapeutic immunization against noninfectious diseases, such as cancer. We review the underlying mechanisms by which engagement of TLR signaling pathways might trigger an adaptive immune response after immunization. Although the engagement of TLR signaling pathways is a promising mechanism for boosting vaccine responses, questions of efficacy, feasibility and safety remain the subject of active investigation. |
| Author | Shaw, Albert C. van Duin, David Medzhitov, Ruslan |
| Author_xml | – sequence: 1 givenname: David surname: van Duin fullname: van Duin, David organization: Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar Street, PO Box 208022, New Haven, CT 06520, USA – sequence: 2 givenname: Ruslan surname: Medzhitov fullname: Medzhitov, Ruslan organization: Section of Immunobiology, Howard Hughes Medical Institute, Yale University School of Medicine, 300 Cedar Street, New Haven, CT 06510, USA – sequence: 3 givenname: Albert C. surname: Shaw fullname: Shaw, Albert C. email: albert.shaw@yale.edu organization: Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar Street, PO Box 208022, New Haven, CT 06520, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16310411$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtLAzEURoMovveupCtddbw3jUnqTsQXFASp65Bm7pRbpxlNpoL_3qn1AS7q6kvgnCxO9sRmbCIJcYRQIKA-mxXcFhLgvEAsutkQu6gM9tXQ4ubPGfSO2Mt5BoDnxphtsYN6gKAQd8XpOPF0SonjtDcePfYyT6OvlzeOvTcfAkffchMPxFbl60yHX7svnm6ux1d3_dHD7f3V5agflLRtfzi0ypugCEuvtfZaVhNTaqisNMaHSlpvJZXkldEelZSqnFigQRnA4wDUYF-crN59Sc3rgnLr5pwD1bWP1CyyM6CHEtD8C6IBqyxgBx5_gYvJnEr3knju07v7btABsAJCanJOVP0i4JaZ3cxx65aZHaLrplP0HyVw-9mpTZ7rdeLFSqSu4RtTcjkwxUAlJwqtKxteJ9s_cuh-ioOvn-l9vfoBnyimKg |
| CitedBy_id | crossref_primary_10_1016_j_bbcan_2007_07_003 crossref_primary_10_1111_j_1365_2567_2011_03551_x crossref_primary_10_1016_j_biomaterials_2008_10_034 crossref_primary_10_1182_blood_2009_11_251884 crossref_primary_10_1128_IAI_01074_12 crossref_primary_10_1038_icb_2011_53 crossref_primary_10_1016_j_vaccine_2013_05_100 crossref_primary_10_1111_j_1365_3083_2006_001764_x crossref_primary_10_1016_j_isci_2020_101250 crossref_primary_10_3389_fimmu_2019_00999 crossref_primary_10_1089_vim_2018_0158 crossref_primary_10_1093_infdis_jix614 crossref_primary_10_4049_jimmunol_1000041 crossref_primary_10_4161_rna_8_5_16154 crossref_primary_10_1158_0008_5472_CAN_12_1740 crossref_primary_10_1016_j_dci_2018_03_013 crossref_primary_10_1016_j_jbiotec_2011_11_006 crossref_primary_10_1021_acs_jmedchem_3c01504 crossref_primary_10_2353_ajpath_2008_071008 crossref_primary_10_4236_wjv_2012_23015 crossref_primary_10_3389_fmolb_2021_719678 crossref_primary_10_1038_ni1386 crossref_primary_10_1111_j_1365_2362_2008_02005_x crossref_primary_10_1016_j_isci_2021_102970 crossref_primary_10_1097_JBR_0000000000000122 crossref_primary_10_3389_fphar_2020_00008 crossref_primary_10_4161_21645515_2014_980682 crossref_primary_10_1016_j_ijfoodmicro_2009_05_013 crossref_primary_10_1111_cei_12841 crossref_primary_10_1038_icb_2009_76 crossref_primary_10_1038_s41598_021_88956_4 crossref_primary_10_4049_jimmunol_181_1_776 crossref_primary_10_1586_erv_11_126 crossref_primary_10_1111_j_1600_0757_2009_00304_x crossref_primary_10_1038_mt_2008_77 crossref_primary_10_1111_j_1749_6632_2010_05787_x crossref_primary_10_1007_s13765_012_2398_5 crossref_primary_10_1111_j_1365_2249_2009_03928_x crossref_primary_10_1016_j_coi_2009_05_003 crossref_primary_10_1016_j_exphem_2007_08_024 crossref_primary_10_1128_CMR_00046_08 crossref_primary_10_1007_s00384_012_1530_7 crossref_primary_10_1155_2020_7418342 crossref_primary_10_1007_s13353_014_0265_2 crossref_primary_10_1016_j_smim_2017_09_007 crossref_primary_10_1645_GE_1309_1 crossref_primary_10_1038_sj_onc_1210909 crossref_primary_10_1016_j_vaccine_2009_01_044 crossref_primary_10_1016_j_intimp_2007_05_014 crossref_primary_10_1016_j_phrs_2020_105293 crossref_primary_10_1002_jps_21523 crossref_primary_10_5483_BMBRep_2016_49_10_080 crossref_primary_10_1038_nrd3087 crossref_primary_10_1051_medsci_200723167 crossref_primary_10_1038_nri2173 crossref_primary_10_1016_j_tracli_2019_01_006 crossref_primary_10_1016_j_intimp_2018_05_012 crossref_primary_10_1080_21645515_2020_1805992 crossref_primary_10_1111_j_1365_2567_2008_02871_x crossref_primary_10_3892_or_2015_4436 crossref_primary_10_3389_fonc_2014_00377 crossref_primary_10_1586_14760584_7_9_1321 crossref_primary_10_1016_j_micinf_2006_03_012 crossref_primary_10_3109_08982104_2011_563364 crossref_primary_10_1136_jitc_2023_007198 crossref_primary_10_4049_jimmunol_180_4_2409 crossref_primary_10_1021_acsinfecdis_1c00434 crossref_primary_10_1021_cb500079s crossref_primary_10_2139_ssrn_4166520 crossref_primary_10_1016_j_molliq_2022_118633 crossref_primary_10_1258_ebm_2012_012181 crossref_primary_10_4049_jimmunol_177_12_8708 crossref_primary_10_3390_immuno2040043 crossref_primary_10_1128_JVI_05441_11 crossref_primary_10_1080_08923970802380452 crossref_primary_10_1016_j_cyto_2015_07_006 crossref_primary_10_1007_s41745_016_0017_x crossref_primary_10_1016_j_micinf_2012_10_007 crossref_primary_10_4049_jimmunol_0901296 crossref_primary_10_1172_jci_insight_93397 crossref_primary_10_1016_j_vaccine_2008_02_044 crossref_primary_10_1111_j_0105_2896_2010_00895_x crossref_primary_10_1016_j_bmc_2016_11_044 crossref_primary_10_1089_jir_2016_0035 crossref_primary_10_1158_0008_5472_CAN_07_1652 crossref_primary_10_1586_erv_10_154 crossref_primary_10_1016_S0895_3988_10_60075_X crossref_primary_10_1371_journal_pone_0023995 crossref_primary_10_1016_j_arr_2010_10_007 crossref_primary_10_1038_mt_2008_8 crossref_primary_10_1371_journal_pone_0013705 crossref_primary_10_1016_j_addr_2017_05_013 crossref_primary_10_1016_j_intimp_2014_02_033 crossref_primary_10_1016_j_vaccine_2007_05_029 crossref_primary_10_1016_j_vaccine_2006_10_055 crossref_primary_10_1016_j_jaci_2012_02_042 crossref_primary_10_2217_imt_09_70 crossref_primary_10_4049_jimmunol_178_11_6710 crossref_primary_10_1016_j_provac_2012_04_011 crossref_primary_10_1016_j_biomaterials_2013_04_005 crossref_primary_10_1099_vir_0_043521_0 crossref_primary_10_1371_journal_pone_0015692 crossref_primary_10_1016_j_jconrel_2025_01_042 crossref_primary_10_1073_pnas_1004661107 crossref_primary_10_1002_eji_201142346 crossref_primary_10_1016_j_nano_2019_102034 crossref_primary_10_4049_jimmunol_1300975 crossref_primary_10_1016_j_vaccine_2022_02_028 crossref_primary_10_3390_vaccines2010001 crossref_primary_10_1007_s11523_013_0285_6 crossref_primary_10_1016_j_vaccine_2011_07_041 crossref_primary_10_1111_j_1365_2567_2009_03146_x crossref_primary_10_1038_s41598_017_00555_4 crossref_primary_10_1586_erv_09_160 crossref_primary_10_1155_2017_3925024 crossref_primary_10_1021_acs_jmedchem_1c00179 crossref_primary_10_1007_s00262_006_0262_3 crossref_primary_10_1016_j_molimm_2014_10_020 crossref_primary_10_1016_j_pep_2014_02_012 crossref_primary_10_4049_jimmunol_181_3_1849 crossref_primary_10_1016_j_intimp_2010_10_014 crossref_primary_10_1016_j_vaccine_2006_04_059 crossref_primary_10_1517_17425247_3_6_747 crossref_primary_10_1016_j_vaccine_2010_11_021 crossref_primary_10_1038_ni_3329 crossref_primary_10_1016_j_vetimm_2013_05_015 crossref_primary_10_1038_ni_1828 crossref_primary_10_1586_14760584_7_2_193 crossref_primary_10_3390_biology9090296 crossref_primary_10_1111_raq_12542 crossref_primary_10_1038_nrd3499 crossref_primary_10_1016_j_vaccine_2012_10_016 crossref_primary_10_3390_s100100097 crossref_primary_10_1111_j_1365_2761_2009_01115_x crossref_primary_10_1182_blood_2007_09_114371 crossref_primary_10_1186_2042_6410_3_25 crossref_primary_10_15789_1563_0625_IAT_1938 crossref_primary_10_1096_fj_11_184556 crossref_primary_10_1007_s00005_009_0025_x crossref_primary_10_3390_v15030775 crossref_primary_10_1002_eji_200738035 crossref_primary_10_1093_intimm_dxr033 crossref_primary_10_1097_CJI_0b013e3181b8ef5f crossref_primary_10_1111_j_1365_2222_2007_02767_x crossref_primary_10_1111_j_1532_5415_2007_01300_x crossref_primary_10_1155_2014_619410 crossref_primary_10_1667_RR13495_1 crossref_primary_10_1002_btpr_10 crossref_primary_10_1016_j_molimm_2008_07_018 crossref_primary_10_1038_ni1530 crossref_primary_10_1097_PPO_0b013e3181eaca65 crossref_primary_10_1016_j_intimp_2008_05_010 crossref_primary_10_1172_JCI81083 crossref_primary_10_1016_j_imlet_2017_10_015 crossref_primary_10_3109_08820131003663357 crossref_primary_10_1039_D4CC00792A crossref_primary_10_1016_j_biomaterials_2012_05_004 crossref_primary_10_1016_j_xphs_2015_11_020 crossref_primary_10_1371_journal_pone_0003665 crossref_primary_10_3389_fimmu_2024_1407649 crossref_primary_10_3390_vaccines1040415 crossref_primary_10_1007_s11033_021_06752_9 crossref_primary_10_1111_imcb_12445 crossref_primary_10_1016_j_ijpharm_2024_124404 crossref_primary_10_1158_1078_0432_CCR_07_0274 crossref_primary_10_3390_vaccines10040607 crossref_primary_10_1007_s00335_010_9269_3 crossref_primary_10_1016_j_leukres_2012_04_007 crossref_primary_10_1038_icb_2008_13 crossref_primary_10_1111_j_1099_0860_2009_00265_x crossref_primary_10_1126_scitranslmed_adk3160 crossref_primary_10_3390_pathogens9040252 crossref_primary_10_3389_fimmu_2018_00947 crossref_primary_10_1016_j_biomaterials_2011_01_061 crossref_primary_10_1136_ard_2007_078998 crossref_primary_10_1189_jlb_0406296 crossref_primary_10_1016_j_jconrel_2008_03_023 crossref_primary_10_1189_jlb_0307166 crossref_primary_10_1007_s10059_009_0015_1 crossref_primary_10_1016_j_toxlet_2011_03_001 crossref_primary_10_1038_nbt_1742 crossref_primary_10_1146_annurev_bioeng_071811_150054 crossref_primary_10_1016_j_molimm_2010_04_004 crossref_primary_10_1038_s41421_021_00370_2 crossref_primary_10_1186_s13567_014_0135_2 crossref_primary_10_1002_ijc_25344 crossref_primary_10_1038_srep41607 crossref_primary_10_1158_0008_5472_CAN_11_1801 crossref_primary_10_1158_0008_5472_CAN_13_2752 crossref_primary_10_1586_ecp_11_5 crossref_primary_10_4049_jimmunol_1100374 crossref_primary_10_1016_j_vaccine_2010_03_014 crossref_primary_10_1021_mp2003835 crossref_primary_10_1186_s12967_017_1152_5 crossref_primary_10_3390_vaccines9040409 crossref_primary_10_1016_j_imbio_2006_05_010 crossref_primary_10_1016_j_vaccine_2009_12_046 crossref_primary_10_1080_00365540802029573 crossref_primary_10_1080_19768354_2011_630411 crossref_primary_10_1016_j_biomaterials_2010_12_021 crossref_primary_10_1016_j_coviro_2012_08_009 crossref_primary_10_1158_0008_5472_CAN_06_3138 crossref_primary_10_1146_annurev_biochem_76_010307_145803 crossref_primary_10_1186_1743_422X_4_133 crossref_primary_10_1128_CVI_00042_13 crossref_primary_10_1016_j_cimid_2012_05_003 crossref_primary_10_1016_j_vaccine_2010_06_117 crossref_primary_10_1080_08830185_2017_1380200 crossref_primary_10_1016_j_drudis_2009_02_009 crossref_primary_10_1089_ars_2010_3723 crossref_primary_10_1073_pnas_0611606104 crossref_primary_10_1517_14712598_2011_573624 crossref_primary_10_1371_journal_pgen_1001249 crossref_primary_10_1071_CH09149 crossref_primary_10_4049_jimmunol_1100486 crossref_primary_10_61186_phypha_28_1_80 crossref_primary_10_18632_aging_101016 crossref_primary_10_1016_j_vaccine_2009_01_103 crossref_primary_10_4049_jimmunol_181_11_7925 crossref_primary_10_1002_chem_201601539 crossref_primary_10_1182_blood_2006_06_027862 crossref_primary_10_1016_S1773_2247_10_50044_3 crossref_primary_10_1038_emi_2016_8 crossref_primary_10_1093_glycob_cwn038 crossref_primary_10_1007_s40843_019_9451_7 crossref_primary_10_1038_gene_2010_14 crossref_primary_10_1080_1744666X_2022_2106217 crossref_primary_10_1080_14760584_2018_1507742 crossref_primary_10_1016_j_cellimm_2010_05_008 crossref_primary_10_1016_j_vaccine_2008_09_045 crossref_primary_10_1128_IAI_00846_07 crossref_primary_10_1016_j_neurol_2022_11_004 crossref_primary_10_1038_mt_2010_223 crossref_primary_10_1016_j_critrevonc_2019_01_009 crossref_primary_10_1586_erv_11_84 crossref_primary_10_1002_smll_202409021 crossref_primary_10_1016_j_molimm_2009_02_006 crossref_primary_10_1111_j_0105_2896_2006_00399_x crossref_primary_10_4049_jimmunol_0901683 crossref_primary_10_1189_jlb_0306147 crossref_primary_10_1007_s00705_015_2704_8 crossref_primary_10_1371_journal_pone_0148701 crossref_primary_10_1016_j_molimm_2010_08_004 crossref_primary_10_1080_21645515_2015_1136039 crossref_primary_10_4049_jimmunol_1301424 crossref_primary_10_4049_jimmunol_1001388 crossref_primary_10_1016_j_vaccine_2010_07_022 crossref_primary_10_1021_acsmedchemlett_1c00267 crossref_primary_10_1126_sciadv_aaz8700 crossref_primary_10_1007_s12602_010_9055_2 crossref_primary_10_1021_acsbiomaterials_4c01478 crossref_primary_10_1073_pnas_0800080105 crossref_primary_10_1080_08830180600743008 crossref_primary_10_3109_08820130903177810 crossref_primary_10_1016_j_patbio_2008_04_003 crossref_primary_10_1016_j_ijid_2013_09_023 crossref_primary_10_3389_fimmu_2019_01659 crossref_primary_10_1371_journal_pone_0048614 crossref_primary_10_1016_j_biomaterials_2016_03_039 crossref_primary_10_1038_nrd3203 crossref_primary_10_1007_s10875_007_9087_x crossref_primary_10_1111_j_1523_5378_2008_00640_x crossref_primary_10_1016_j_cyto_2007_11_014 crossref_primary_10_1016_j_jconrel_2010_09_018 |
| Cites_doi | 10.1128/IAI.71.7.3894-3900.2003 10.1001/jama.271.9.698 10.1517/14712598.4.7.1129 10.1111/j.1365-2567.2004.01938.x 10.1038/nm732 10.1016/j.vaccine.2003.10.051 10.1128/JVI.79.6.3297-3308.2005 10.1086/317537 10.1182/blood.V92.10.3730 10.1158/0008-5472.CAN-03-1518 10.1172/JCI200421027 10.1128/JVI.76.17.8729-8736.2002 10.4049/jimmunol.170.1.194 10.4049/jimmunol.169.7.3914 10.1038/ni1059 10.1016/j.it.2005.07.002 10.1084/jem.20021340 10.1006/cimm.2001.1883 10.4049/jimmunol.174.12.7676 10.1016/S0264-410X(02)00702-8 10.1126/science.285.5428.732 10.4049/jimmunol.167.11.6644 10.1023/B:EJEP.0000032423.87658.68 10.4049/jimmunol.174.3.1539 10.1128/IAI.68.12.6883-6890.2000 10.4049/jimmunol.171.1.32 10.1002/eji.200425166 10.1016/S0264-410X(01)00241-9 10.1016/S1074-7613(02)00278-9 10.4049/jimmunol.171.11.5908 10.4049/jimmunol.166.4.2444 10.1073/pnas.0400937101 10.1038/nm987 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J 10.4049/jimmunol.173.4.2683 10.4049/jimmunol.170.10.5165 10.1073/pnas.0406740101 10.4049/jimmunol.172.4.2431 10.1172/JCI23373 10.1016/S0140-6736(98)07186-4 10.1146/annurev.immunol.21.120601.141126 10.1126/science.1078231 10.4049/jimmunol.171.5.2538 10.4049/jimmunol.164.2.554 10.1038/10495 10.1038/42030 10.1038/nri1001 10.1007/s00281-004-0168-0 10.1016/S1074-7613(03)00327-3 10.1016/j.coi.2005.04.004 10.1016/S0264-410X(02)00737-5 10.1038/nature03326 10.4049/jimmunol.172.3.1501 10.1038/ni1112 10.1046/j.0366-077X.2003.05626.x 10.4049/jimmunol.168.4.1533 10.1056/NEJM199807233390401 10.1128/IAI.71.10.5590-5597.2003 10.1007/s10434-001-0389-6 10.4049/jimmunol.167.2.987 10.1086/428404 10.1016/j.vaccine.2004.09.001 10.1111/j.0105-2896.2005.00235.x 10.4049/jimmunol.170.8.4102 10.4049/jimmunol.163.7.3920 10.4049/jimmunol.171.10.5611 10.1126/science.1075565 10.1038/ni712 10.1016/j.urology.2004.04.026 10.1038/sj.gt.3302358 10.1126/science.1113401 10.1016/j.it.2004.04.011 10.1016/j.vaccine.2004.01.037 10.1111/j.0105-2896.2004.00148.x 10.4049/jimmunol.172.3.1347 10.1038/416603a 10.1038/ni1010 10.1038/75365 |
| ContentType | Journal Article |
| Copyright | 2005 Elsevier Ltd |
| Copyright_xml | – notice: 2005 Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 |
| DOI | 10.1016/j.it.2005.11.005 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1471-4981 1365-2567 |
| EndPage | 55 |
| ExternalDocumentID | 16310411 10_1016_j_it_2005_11_005 S1471490605002863 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: T32 AI007517 – fundername: NIAID NIH HHS grantid: N01AI50031 – fundername: NCRR NIH HHS grantid: K12RR17594 |
| GroupedDBID | --- --K --M -DZ .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 2KS 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8FE 8FH 8P~ 9M8 AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABEFU ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKEYQ BKOJK BLXMC BPHCQ BVXVI CJTIS CS3 D0L DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IH2 IHE J1W KOM L7B LK8 LUGTX M41 MO0 MVM N9A O-L O9- O9~ OAUVE OK0 OMK OZT P-8 P-9 PC. PQQKQ PROAC Q38 R2- ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SSZ T5K WOW X7M XJT XPP Y6R Z5R ZCG ZGI ~G- 3V. 7RV 7X7 8FI AACTN AAIAV ABYKQ AFCTW AFDAS AFKRA AFKWA AHPSJ AJBFU AJOXV AMFUW AZQEC BBNVY BENPR BHPHI EFLBG FYUFA GUQSH HCIFZ LCYCR M1P M2O M7P RCE RIG SSI VQA XFK ZA5 AAYXX AGRNS BNPGV CITATION SSH CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 |
| ID | FETCH-LOGICAL-c428t-9984a7c4e1da666a62fb7d60f8277acf28a82edea476a14224db80e3dc0a13043 |
| IEDL.DBID | AIKHN |
| ISSN | 1471-4906 |
| IngestDate | Fri Jul 11 00:27:23 EDT 2025 Fri Jul 11 00:20:23 EDT 2025 Wed Feb 19 02:34:19 EST 2025 Tue Jul 01 02:14:30 EDT 2025 Thu Apr 24 22:52:08 EDT 2025 Fri Feb 23 02:15:19 EST 2024 Tue Aug 26 16:32:11 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c428t-9984a7c4e1da666a62fb7d60f8277acf28a82edea476a14224db80e3dc0a13043 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 |
| PMID | 16310411 |
| PQID | 17084801 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_70692017 proquest_miscellaneous_17084801 pubmed_primary_16310411 crossref_primary_10_1016_j_it_2005_11_005 crossref_citationtrail_10_1016_j_it_2005_11_005 elsevier_sciencedirect_doi_10_1016_j_it_2005_11_005 elsevier_clinicalkey_doi_10_1016_j_it_2005_11_005 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2006 2006-1-00 2006-Jan 20060101 |
| PublicationDateYYYYMMDD | 2006-01-01 |
| PublicationDate_xml | – year: 2006 text: 2006 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Trends in Immunology |
| PublicationTitleAlternate | Trends Immunol |
| PublicationYear | 2006 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Otero (bib77) 2004; 22 Latz (bib50) 2004; 172 Babiuk (bib28) 2004; 113 Bulut (bib41) 2001; 167 Cella (bib15) 1997; 388 Przetak (bib74) 2003; 21 Tsuji (bib47) 2000; 68 Colditz (bib46) 1994; 271 Biragyn (bib64) 2001; 167 Sieling (bib70) 2003; 170 Schulz (bib23) 2005; 433 Habal (bib66) 2001; 8 Baldridge (bib63) 2004; 4 Klinman (bib26) 2004; 199 Spellberg, Edwards (bib4) 2001; 32 Schnare (bib72) 2001; 2 Datta (bib25) 2003; 170 Zuber (bib76) 2004; 22 Serra (bib37) 2003; 19 Chen (bib20) 2001; 214 Speiser (bib61) 2005; 115 Jankovic (bib8) 2002; 16 Tritel (bib54) 2003; 171 Spies (bib27) 2003; 171 Kochling (bib59) 2003; 9 Lemckert (bib53) 2004; 19 Takeuchi (bib71) 2000; 164 Jackson (bib34) 2004; 101 Iwasaki, Medzhitov (bib3) 2004; 5 Schjetne (bib33) 2003; 171 Trinchieri (bib7) 2003; 3 Flynn (bib56) 2005; 191 Eo (bib14) 2001; 19 Means (bib11) 2003; 170 Hertz (bib16) 2001; 166 Wagner (bib30) 2004; 25 Andre (bib1) 2003; 21 Wilson (bib55) 2003; 171 Shackleton (bib62) 2004; 4 Diehl (bib18) 1999; 5 Ku (bib39) 2005; 203 Okada (bib13) 2005; 12 Schroder, Bowie (bib22) 2005; 26 Perabo, Muller (bib69) 2004; 64 Wille-Reece (bib78) 2005; 174 Akazawa (bib65) 2004; 64 Stockfleth (bib68) 2003; 149 Liu (bib57) 1998; 92 Fremond (bib49) 2004; 114 Tudor (bib29) 2005; 23 Heckelsmiller (bib60) 2002; 32 Massari (bib51) 2002; 168 Bieback (bib80) 2002; 76 Cho (bib58) 2000; 8 McSorley (bib75) 2002; 169 Pasare, Medzhitov (bib35) 2003; 299 Leadbetter (bib31) 2002; 416 Yoder (bib43) 2003; 71 Vermorken (bib67) 1999; 353 Randolph (bib12) 2005; 26 Yamaguchi (bib19) 2004; 172 Steere (bib40) 1998; 339 Osorio, Ghiasi (bib10) 2005; 79 Yang (bib36) 2004; 5 Hoebe (bib17) 2003; 4 Eisenbarth (bib5) 2002; 196 Heikenwalder (bib32) 2004; 10 Al-Bader (bib52) 2003; 71 Brightbill (bib6) 1999; 285 Benhnia (bib45) 2005; 174 Takeda (bib2) 2003; 21 Borst (bib21) 2005; 17 Heit (bib24) 2004; 172 Means (bib48) 1999; 163 Alexopoulou (bib42) 2002; 8 Zhu (bib9) 2004; 34 Peng (bib38) 2005; 309 Lund (bib79) 2004; 101 Schroder (bib44) 2004; 173 Biragyn (bib73) 2002; 298 Baldridge (10.1016/j.it.2005.11.005_bib63) 2004; 4 Pasare (10.1016/j.it.2005.11.005_bib35) 2003; 299 Kochling (10.1016/j.it.2005.11.005_bib59) 2003; 9 Okada (10.1016/j.it.2005.11.005_bib13) 2005; 12 McSorley (10.1016/j.it.2005.11.005_bib75) 2002; 169 Klinman (10.1016/j.it.2005.11.005_bib26) 2004; 199 Yamaguchi (10.1016/j.it.2005.11.005_bib19) 2004; 172 Cho (10.1016/j.it.2005.11.005_bib58) 2000; 8 Schulz (10.1016/j.it.2005.11.005_bib23) 2005; 433 Heckelsmiller (10.1016/j.it.2005.11.005_bib60) 2002; 32 Tudor (10.1016/j.it.2005.11.005_bib29) 2005; 23 Bieback (10.1016/j.it.2005.11.005_bib80) 2002; 76 Leadbetter (10.1016/j.it.2005.11.005_bib31) 2002; 416 Schjetne (10.1016/j.it.2005.11.005_bib33) 2003; 171 Colditz (10.1016/j.it.2005.11.005_bib46) 1994; 271 Schroder (10.1016/j.it.2005.11.005_bib44) 2004; 173 Borst (10.1016/j.it.2005.11.005_bib21) 2005; 17 Eo (10.1016/j.it.2005.11.005_bib14) 2001; 19 Schnare (10.1016/j.it.2005.11.005_bib72) 2001; 2 Iwasaki (10.1016/j.it.2005.11.005_bib3) 2004; 5 Takeda (10.1016/j.it.2005.11.005_bib2) 2003; 21 Bulut (10.1016/j.it.2005.11.005_bib41) 2001; 167 Eisenbarth (10.1016/j.it.2005.11.005_bib5) 2002; 196 Wilson (10.1016/j.it.2005.11.005_bib55) 2003; 171 Perabo (10.1016/j.it.2005.11.005_bib69) 2004; 64 Stockfleth (10.1016/j.it.2005.11.005_bib68) 2003; 149 Takeuchi (10.1016/j.it.2005.11.005_bib71) 2000; 164 Spellberg (10.1016/j.it.2005.11.005_bib4) 2001; 32 Andre (10.1016/j.it.2005.11.005_bib1) 2003; 21 Spies (10.1016/j.it.2005.11.005_bib27) 2003; 171 Otero (10.1016/j.it.2005.11.005_bib77) 2004; 22 Latz (10.1016/j.it.2005.11.005_bib50) 2004; 172 Brightbill (10.1016/j.it.2005.11.005_bib6) 1999; 285 Vermorken (10.1016/j.it.2005.11.005_bib67) 1999; 353 Flynn (10.1016/j.it.2005.11.005_bib56) 2005; 191 Shackleton (10.1016/j.it.2005.11.005_bib62) 2004; 4 Jackson (10.1016/j.it.2005.11.005_bib34) 2004; 101 Chen (10.1016/j.it.2005.11.005_bib20) 2001; 214 Trinchieri (10.1016/j.it.2005.11.005_bib7) 2003; 3 Heit (10.1016/j.it.2005.11.005_bib24) 2004; 172 Cella (10.1016/j.it.2005.11.005_bib15) 1997; 388 Means (10.1016/j.it.2005.11.005_bib11) 2003; 170 Steere (10.1016/j.it.2005.11.005_bib40) 1998; 339 Biragyn (10.1016/j.it.2005.11.005_bib64) 2001; 167 Zuber (10.1016/j.it.2005.11.005_bib76) 2004; 22 Serra (10.1016/j.it.2005.11.005_bib37) 2003; 19 Sieling (10.1016/j.it.2005.11.005_bib70) 2003; 170 Means (10.1016/j.it.2005.11.005_bib48) 1999; 163 Lemckert (10.1016/j.it.2005.11.005_bib53) 2004; 19 Tsuji (10.1016/j.it.2005.11.005_bib47) 2000; 68 Fremond (10.1016/j.it.2005.11.005_bib49) 2004; 114 Diehl (10.1016/j.it.2005.11.005_bib18) 1999; 5 Heikenwalder (10.1016/j.it.2005.11.005_bib32) 2004; 10 Yang (10.1016/j.it.2005.11.005_bib36) 2004; 5 Randolph (10.1016/j.it.2005.11.005_bib12) 2005; 26 Schroder (10.1016/j.it.2005.11.005_bib22) 2005; 26 Peng (10.1016/j.it.2005.11.005_bib38) 2005; 309 Przetak (10.1016/j.it.2005.11.005_bib74) 2003; 21 Osorio (10.1016/j.it.2005.11.005_bib10) 2005; 79 Massari (10.1016/j.it.2005.11.005_bib51) 2002; 168 Jankovic (10.1016/j.it.2005.11.005_bib8) 2002; 16 Wille-Reece (10.1016/j.it.2005.11.005_bib78) 2005; 174 Datta (10.1016/j.it.2005.11.005_bib25) 2003; 170 Ku (10.1016/j.it.2005.11.005_bib39) 2005; 203 Liu (10.1016/j.it.2005.11.005_bib57) 1998; 92 Alexopoulou (10.1016/j.it.2005.11.005_bib42) 2002; 8 Zhu (10.1016/j.it.2005.11.005_bib9) 2004; 34 Hoebe (10.1016/j.it.2005.11.005_bib17) 2003; 4 Al-Bader (10.1016/j.it.2005.11.005_bib52) 2003; 71 Hertz (10.1016/j.it.2005.11.005_bib16) 2001; 166 Habal (10.1016/j.it.2005.11.005_bib66) 2001; 8 Biragyn (10.1016/j.it.2005.11.005_bib73) 2002; 298 Tritel (10.1016/j.it.2005.11.005_bib54) 2003; 171 Yoder (10.1016/j.it.2005.11.005_bib43) 2003; 71 Wagner (10.1016/j.it.2005.11.005_bib30) 2004; 25 Benhnia (10.1016/j.it.2005.11.005_bib45) 2005; 174 Lund (10.1016/j.it.2005.11.005_bib79) 2004; 101 Babiuk (10.1016/j.it.2005.11.005_bib28) 2004; 113 Speiser (10.1016/j.it.2005.11.005_bib61) 2005; 115 Akazawa (10.1016/j.it.2005.11.005_bib65) 2004; 64 |
| References_xml | – volume: 71 start-page: 3894 year: 2003 end-page: 3900 ident: bib43 article-title: Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of Toll-like receptor 2-deficient mice results in effective protection from publication-title: Infect. Immun. – volume: 2 start-page: 947 year: 2001 end-page: 950 ident: bib72 article-title: Toll-like receptors control activation of adaptive immune responses publication-title: Nat. Immunol. – volume: 8 start-page: 509 year: 2000 end-page: 514 ident: bib58 article-title: Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism publication-title: Nat. Biotechnol. – volume: 433 start-page: 887 year: 2005 end-page: 892 ident: bib23 article-title: Toll-like receptor 3 promotes cross-priming to virus-infected cells publication-title: Nature – volume: 16 start-page: 429 year: 2002 end-page: 439 ident: bib8 article-title: In the absence of IL-12, CD4+ T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10−/− setting publication-title: Immunity – volume: 170 start-page: 4102 year: 2003 end-page: 4110 ident: bib25 article-title: A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells publication-title: J. Immunol. – volume: 171 start-page: 5611 year: 2003 end-page: 5623 ident: bib55 article-title: Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1 publication-title: J. Immunol. – volume: 9 start-page: 3142 year: 2003 end-page: 3149 ident: bib59 article-title: Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides publication-title: Clin. Cancer Res. – volume: 173 start-page: 2683 year: 2004 end-page: 2691 ident: bib44 article-title: Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses publication-title: J. Immunol. – volume: 299 start-page: 1033 year: 2003 end-page: 1036 ident: bib35 article-title: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells publication-title: Science – volume: 196 start-page: 1645 year: 2002 end-page: 1651 ident: bib5 article-title: Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen publication-title: J. Exp. Med. – volume: 353 start-page: 345 year: 1999 end-page: 350 ident: bib67 article-title: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial publication-title: Lancet – volume: 174 start-page: 1539 year: 2005 end-page: 1548 ident: bib45 article-title: Signaling through CD14 attenuates the inflammatory response to publication-title: J. Immunol. – volume: 26 start-page: 462 year: 2005 end-page: 468 ident: bib22 article-title: TLR3 in antiviral immunity: key player or bystander? publication-title: Trends Immunol. – volume: 4 start-page: 1223 year: 2003 end-page: 1229 ident: bib17 article-title: Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways publication-title: Nat. Immunol. – volume: 68 start-page: 6883 year: 2000 end-page: 6890 ident: bib47 article-title: Maturation of human dendritic cells by cell wall skeleton of publication-title: Infect. Immun. – volume: 115 start-page: 739 year: 2005 end-page: 746 ident: bib61 article-title: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 publication-title: J. Clin. Invest. – volume: 169 start-page: 3914 year: 2002 end-page: 3919 ident: bib75 article-title: Bacterial flagellin is an effective adjuvant for CD4+ T cells publication-title: J. Immunol. – volume: 271 start-page: 698 year: 1994 end-page: 702 ident: bib46 article-title: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature publication-title: JAMA – volume: 166 start-page: 2444 year: 2001 end-page: 2450 ident: bib16 article-title: Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2 publication-title: J. Immunol. – volume: 168 start-page: 1533 year: 2002 end-page: 1537 ident: bib51 article-title: Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent publication-title: J. Immunol. – volume: 8 start-page: 878 year: 2002 end-page: 884 ident: bib42 article-title: Hyporesponsiveness to vaccination with publication-title: Nat. Med. – volume: 101 start-page: 5598 year: 2004 end-page: 5603 ident: bib79 article-title: Recognition of single-stranded RNA viruses by Toll-like receptor 7 publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 172 start-page: 1501 year: 2004 end-page: 1507 ident: bib24 article-title: CpG-DNA aided cross-priming by cross-presenting B cells publication-title: J. Immunol. – volume: 285 start-page: 732 year: 1999 end-page: 736 ident: bib6 article-title: Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors publication-title: Science – volume: 5 start-page: 774 year: 1999 end-page: 779 ident: bib18 article-title: CD40 activation publication-title: Nat. Med. – volume: 64 start-page: 757 year: 2004 end-page: 764 ident: bib65 article-title: Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice publication-title: Cancer Res. – volume: 191 start-page: 654 year: 2005 end-page: 665 ident: bib56 article-title: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection publication-title: J. Infect. Dis. – volume: 17 start-page: 275 year: 2005 end-page: 281 ident: bib21 article-title: CD27 and CD70 in T cell and B cell activation publication-title: Curr. Opin. Immunol. – volume: 339 start-page: 209 year: 1998 end-page: 215 ident: bib40 article-title: Vaccination against Lyme disease with recombinant publication-title: N. Engl. J. Med. – volume: 114 start-page: 1790 year: 2004 end-page: 1799 ident: bib49 article-title: Fatal publication-title: J. Clin. Invest. – volume: 174 start-page: 7676 year: 2005 end-page: 7683 ident: bib78 article-title: Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses publication-title: J. Immunol. – volume: 76 start-page: 8729 year: 2002 end-page: 8736 ident: bib80 article-title: Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling publication-title: J. Virol. – volume: 64 start-page: 409 year: 2004 end-page: 421 ident: bib69 article-title: Current and new strategies in immunotherapy for superficial bladder cancer publication-title: Urology – volume: 32 start-page: 3235 year: 2002 end-page: 3245 ident: bib60 article-title: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy publication-title: Eur. J. Immunol. – volume: 101 start-page: 15440 year: 2004 end-page: 15445 ident: bib34 article-title: A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 149 start-page: 53 year: 2003 end-page: 56 ident: bib68 article-title: The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview publication-title: Br. J. Dermatol. – volume: 170 start-page: 5165 year: 2003 end-page: 5175 ident: bib11 article-title: The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells publication-title: J. Immunol. – volume: 171 start-page: 2538 year: 2003 end-page: 2547 ident: bib54 article-title: Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses publication-title: J. Immunol. – volume: 92 start-page: 3730 year: 1998 end-page: 3736 ident: bib57 article-title: Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor publication-title: Blood – volume: 416 start-page: 603 year: 2002 end-page: 607 ident: bib31 article-title: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors publication-title: Nature – volume: 172 start-page: 1347 year: 2004 end-page: 1354 ident: bib19 article-title: Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production publication-title: J. Immunol. – volume: 21 start-page: 961 year: 2003 end-page: 970 ident: bib74 article-title: Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice publication-title: Vaccine – volume: 170 start-page: 194 year: 2003 end-page: 200 ident: bib70 article-title: Toll-like receptor 2 ligands as adjuvants for human Th1 responses publication-title: J. Immunol. – volume: 25 start-page: 381 year: 2004 end-page: 386 ident: bib30 article-title: The immunobiology of the TLR9 subfamily publication-title: Trends Immunol. – volume: 171 start-page: 5908 year: 2003 end-page: 5912 ident: bib27 article-title: Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice publication-title: J. Immunol. – volume: 203 start-page: 10 year: 2005 end-page: 20 ident: bib39 article-title: Inherited disorders of human Toll-like receptor signaling: immunological implications publication-title: Immunol. Rev. – volume: 12 start-page: 129 year: 2005 end-page: 139 ident: bib13 article-title: Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction publication-title: Gene Ther. – volume: 167 start-page: 6644 year: 2001 end-page: 6653 ident: bib64 article-title: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens publication-title: J. Immunol. – volume: 388 start-page: 782 year: 1997 end-page: 787 ident: bib15 article-title: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells publication-title: Nature – volume: 5 start-page: 508 year: 2004 end-page: 515 ident: bib36 article-title: Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance publication-title: Nat. Immunol. – volume: 32 start-page: 76 year: 2001 end-page: 102 ident: bib4 article-title: Type 1/Type 2 immunity in infectious diseases publication-title: Clin. Infect. Dis. – volume: 71 start-page: 5590 year: 2003 end-page: 5597 ident: bib52 article-title: Activation of human dendritic cells is modulated by components of the outer membranes of publication-title: Infect. Immun. – volume: 8 start-page: 389 year: 2001 end-page: 401 ident: bib66 article-title: CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer publication-title: Ann. Surg. Oncol. – volume: 163 start-page: 3920 year: 1999 end-page: 3927 ident: bib48 article-title: Human Toll-like receptors mediate cellular activation by publication-title: J. Immunol. – volume: 199 start-page: 201 year: 2004 end-page: 216 ident: bib26 article-title: Use of CpG oligodeoxynucleotides as immune adjuvants publication-title: Immunol. Rev. – volume: 309 start-page: 1380 year: 2005 end-page: 1384 ident: bib38 article-title: Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function publication-title: Science – volume: 19 start-page: 513 year: 2004 end-page: 516 ident: bib53 article-title: Challenges in the search for an HIV vaccine publication-title: Eur. J. Epidemiol. – volume: 21 start-page: 593 year: 2003 end-page: 595 ident: bib1 article-title: Vaccinology: past achievements, present roadblocks and future promises publication-title: Vaccine – volume: 34 start-page: 3102 year: 2004 end-page: 3114 ident: bib9 article-title: Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity publication-title: Eur. J. Immunol. – volume: 3 start-page: 133 year: 2003 end-page: 146 ident: bib7 article-title: Interleukin-12 and the regulation of innate resistance and adaptive immunity publication-title: Nat. Rev. Immunol. – volume: 19 start-page: 4685 year: 2001 end-page: 4693 ident: bib14 article-title: Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands publication-title: Vaccine – volume: 164 start-page: 554 year: 2000 end-page: 557 ident: bib71 article-title: Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway publication-title: J. Immunol. – volume: 10 start-page: 187 year: 2004 end-page: 192 ident: bib32 article-title: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration publication-title: Nat. Med. – volume: 22 start-page: 1791 year: 2004 end-page: 1798 ident: bib76 article-title: Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA publication-title: Vaccine – volume: 171 start-page: 32 year: 2003 end-page: 36 ident: bib33 article-title: Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target publication-title: J. Immunol. – volume: 21 start-page: 335 year: 2003 end-page: 376 ident: bib2 article-title: Toll-like receptors publication-title: Annu. Rev. Immunol. – volume: 4 start-page: 9 year: 2004 end-page: 20 ident: bib62 article-title: The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand publication-title: Cancer Immun. – volume: 167 start-page: 987 year: 2001 end-page: 994 ident: bib41 article-title: Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and publication-title: J. Immunol. – volume: 4 start-page: 1129 year: 2004 end-page: 1138 ident: bib63 article-title: Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents publication-title: Expert Opin. Biol. Ther. – volume: 19 start-page: 877 year: 2003 end-page: 889 ident: bib37 article-title: CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells publication-title: Immunity – volume: 172 start-page: 2431 year: 2004 end-page: 2438 ident: bib50 publication-title: J. Immunol. – volume: 79 start-page: 3297 year: 2005 end-page: 3308 ident: bib10 article-title: Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge publication-title: J. Virol. – volume: 214 start-page: 60 year: 2001 end-page: 71 ident: bib20 article-title: DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy publication-title: Cell. Immunol. – volume: 5 start-page: 987 year: 2004 end-page: 995 ident: bib3 article-title: Toll-like receptor control of the adaptive immune responses publication-title: Nat. Immunol. – volume: 298 start-page: 1025 year: 2002 end-page: 1029 ident: bib73 article-title: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2 publication-title: Science – volume: 22 start-page: 1782 year: 2004 end-page: 1790 ident: bib77 article-title: Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model publication-title: Vaccine – volume: 23 start-page: 1258 year: 2005 end-page: 1264 ident: bib29 article-title: TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines publication-title: Vaccine – volume: 26 start-page: 273 year: 2005 end-page: 287 ident: bib12 article-title: Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances publication-title: Springer Semin. Immunopathol. – volume: 113 start-page: 114 year: 2004 end-page: 120 ident: bib28 article-title: TLR9−/− and TLR9+/+ mice display similar immune responses to a DNA vaccine publication-title: Immunology – volume: 71 start-page: 3894 year: 2003 ident: 10.1016/j.it.2005.11.005_bib43 article-title: Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of Toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge publication-title: Infect. Immun. doi: 10.1128/IAI.71.7.3894-3900.2003 – volume: 271 start-page: 698 year: 1994 ident: 10.1016/j.it.2005.11.005_bib46 article-title: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature publication-title: JAMA doi: 10.1001/jama.271.9.698 – volume: 4 start-page: 9 year: 2004 ident: 10.1016/j.it.2005.11.005_bib62 article-title: The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand publication-title: Cancer Immun. – volume: 4 start-page: 1129 year: 2004 ident: 10.1016/j.it.2005.11.005_bib63 article-title: Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents publication-title: Expert Opin. Biol. Ther. doi: 10.1517/14712598.4.7.1129 – volume: 113 start-page: 114 year: 2004 ident: 10.1016/j.it.2005.11.005_bib28 article-title: TLR9−/− and TLR9+/+ mice display similar immune responses to a DNA vaccine publication-title: Immunology doi: 10.1111/j.1365-2567.2004.01938.x – volume: 8 start-page: 878 year: 2002 ident: 10.1016/j.it.2005.11.005_bib42 article-title: Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice publication-title: Nat. Med. doi: 10.1038/nm732 – volume: 22 start-page: 1791 year: 2004 ident: 10.1016/j.it.2005.11.005_bib76 article-title: Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA publication-title: Vaccine doi: 10.1016/j.vaccine.2003.10.051 – volume: 79 start-page: 3297 year: 2005 ident: 10.1016/j.it.2005.11.005_bib10 article-title: Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge publication-title: J. Virol. doi: 10.1128/JVI.79.6.3297-3308.2005 – volume: 32 start-page: 76 year: 2001 ident: 10.1016/j.it.2005.11.005_bib4 article-title: Type 1/Type 2 immunity in infectious diseases publication-title: Clin. Infect. Dis. doi: 10.1086/317537 – volume: 92 start-page: 3730 year: 1998 ident: 10.1016/j.it.2005.11.005_bib57 article-title: Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor publication-title: Blood doi: 10.1182/blood.V92.10.3730 – volume: 64 start-page: 757 year: 2004 ident: 10.1016/j.it.2005.11.005_bib65 article-title: Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-03-1518 – volume: 114 start-page: 1790 year: 2004 ident: 10.1016/j.it.2005.11.005_bib49 article-title: Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88 publication-title: J. Clin. Invest. doi: 10.1172/JCI200421027 – volume: 76 start-page: 8729 year: 2002 ident: 10.1016/j.it.2005.11.005_bib80 article-title: Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling publication-title: J. Virol. doi: 10.1128/JVI.76.17.8729-8736.2002 – volume: 170 start-page: 194 year: 2003 ident: 10.1016/j.it.2005.11.005_bib70 article-title: Toll-like receptor 2 ligands as adjuvants for human Th1 responses publication-title: J. Immunol. doi: 10.4049/jimmunol.170.1.194 – volume: 169 start-page: 3914 year: 2002 ident: 10.1016/j.it.2005.11.005_bib75 article-title: Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo publication-title: J. Immunol. doi: 10.4049/jimmunol.169.7.3914 – volume: 5 start-page: 508 year: 2004 ident: 10.1016/j.it.2005.11.005_bib36 article-title: Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance publication-title: Nat. Immunol. doi: 10.1038/ni1059 – volume: 26 start-page: 462 year: 2005 ident: 10.1016/j.it.2005.11.005_bib22 article-title: TLR3 in antiviral immunity: key player or bystander? publication-title: Trends Immunol. doi: 10.1016/j.it.2005.07.002 – volume: 196 start-page: 1645 year: 2002 ident: 10.1016/j.it.2005.11.005_bib5 article-title: Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen publication-title: J. Exp. Med. doi: 10.1084/jem.20021340 – volume: 214 start-page: 60 year: 2001 ident: 10.1016/j.it.2005.11.005_bib20 article-title: DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy publication-title: Cell. Immunol. doi: 10.1006/cimm.2001.1883 – volume: 174 start-page: 7676 year: 2005 ident: 10.1016/j.it.2005.11.005_bib78 article-title: Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses publication-title: J. Immunol. doi: 10.4049/jimmunol.174.12.7676 – volume: 21 start-page: 593 year: 2003 ident: 10.1016/j.it.2005.11.005_bib1 article-title: Vaccinology: past achievements, present roadblocks and future promises publication-title: Vaccine doi: 10.1016/S0264-410X(02)00702-8 – volume: 285 start-page: 732 year: 1999 ident: 10.1016/j.it.2005.11.005_bib6 article-title: Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors publication-title: Science doi: 10.1126/science.285.5428.732 – volume: 167 start-page: 6644 year: 2001 ident: 10.1016/j.it.2005.11.005_bib64 article-title: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens publication-title: J. Immunol. doi: 10.4049/jimmunol.167.11.6644 – volume: 19 start-page: 513 year: 2004 ident: 10.1016/j.it.2005.11.005_bib53 article-title: Challenges in the search for an HIV vaccine publication-title: Eur. J. Epidemiol. doi: 10.1023/B:EJEP.0000032423.87658.68 – volume: 174 start-page: 1539 year: 2005 ident: 10.1016/j.it.2005.11.005_bib45 article-title: Signaling through CD14 attenuates the inflammatory response to Borrelia burgdorferi, the agent of Lyme disease publication-title: J. Immunol. doi: 10.4049/jimmunol.174.3.1539 – volume: 68 start-page: 6883 year: 2000 ident: 10.1016/j.it.2005.11.005_bib47 article-title: Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of Toll-like receptors publication-title: Infect. Immun. doi: 10.1128/IAI.68.12.6883-6890.2000 – volume: 171 start-page: 32 year: 2003 ident: 10.1016/j.it.2005.11.005_bib33 article-title: Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target publication-title: J. Immunol. doi: 10.4049/jimmunol.171.1.32 – volume: 34 start-page: 3102 year: 2004 ident: 10.1016/j.it.2005.11.005_bib9 article-title: Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity publication-title: Eur. J. Immunol. doi: 10.1002/eji.200425166 – volume: 19 start-page: 4685 year: 2001 ident: 10.1016/j.it.2005.11.005_bib14 article-title: Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands publication-title: Vaccine doi: 10.1016/S0264-410X(01)00241-9 – volume: 16 start-page: 429 year: 2002 ident: 10.1016/j.it.2005.11.005_bib8 article-title: In the absence of IL-12, CD4+ T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10−/− setting publication-title: Immunity doi: 10.1016/S1074-7613(02)00278-9 – volume: 171 start-page: 5908 year: 2003 ident: 10.1016/j.it.2005.11.005_bib27 article-title: Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice publication-title: J. Immunol. doi: 10.4049/jimmunol.171.11.5908 – volume: 166 start-page: 2444 year: 2001 ident: 10.1016/j.it.2005.11.005_bib16 article-title: Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2 publication-title: J. Immunol. doi: 10.4049/jimmunol.166.4.2444 – volume: 101 start-page: 5598 year: 2004 ident: 10.1016/j.it.2005.11.005_bib79 article-title: Recognition of single-stranded RNA viruses by Toll-like receptor 7 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0400937101 – volume: 10 start-page: 187 year: 2004 ident: 10.1016/j.it.2005.11.005_bib32 article-title: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration publication-title: Nat. Med. doi: 10.1038/nm987 – volume: 32 start-page: 3235 year: 2002 ident: 10.1016/j.it.2005.11.005_bib60 article-title: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy publication-title: Eur. J. Immunol. doi: 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J – volume: 173 start-page: 2683 year: 2004 ident: 10.1016/j.it.2005.11.005_bib44 article-title: Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses publication-title: J. Immunol. doi: 10.4049/jimmunol.173.4.2683 – volume: 170 start-page: 5165 year: 2003 ident: 10.1016/j.it.2005.11.005_bib11 article-title: The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells publication-title: J. Immunol. doi: 10.4049/jimmunol.170.10.5165 – volume: 101 start-page: 15440 year: 2004 ident: 10.1016/j.it.2005.11.005_bib34 article-title: A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0406740101 – volume: 172 start-page: 2431 year: 2004 ident: 10.1016/j.it.2005.11.005_bib50 article-title: Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human Toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity publication-title: J. Immunol. doi: 10.4049/jimmunol.172.4.2431 – volume: 115 start-page: 739 year: 2005 ident: 10.1016/j.it.2005.11.005_bib61 article-title: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909 publication-title: J. Clin. Invest. doi: 10.1172/JCI23373 – volume: 353 start-page: 345 year: 1999 ident: 10.1016/j.it.2005.11.005_bib67 article-title: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(98)07186-4 – volume: 21 start-page: 335 year: 2003 ident: 10.1016/j.it.2005.11.005_bib2 article-title: Toll-like receptors publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.21.120601.141126 – volume: 299 start-page: 1033 year: 2003 ident: 10.1016/j.it.2005.11.005_bib35 article-title: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells publication-title: Science doi: 10.1126/science.1078231 – volume: 171 start-page: 2538 year: 2003 ident: 10.1016/j.it.2005.11.005_bib54 article-title: Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses publication-title: J. Immunol. doi: 10.4049/jimmunol.171.5.2538 – volume: 164 start-page: 554 year: 2000 ident: 10.1016/j.it.2005.11.005_bib71 article-title: Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway publication-title: J. Immunol. doi: 10.4049/jimmunol.164.2.554 – volume: 5 start-page: 774 year: 1999 ident: 10.1016/j.it.2005.11.005_bib18 article-title: CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy publication-title: Nat. Med. doi: 10.1038/10495 – volume: 388 start-page: 782 year: 1997 ident: 10.1016/j.it.2005.11.005_bib15 article-title: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells publication-title: Nature doi: 10.1038/42030 – volume: 3 start-page: 133 year: 2003 ident: 10.1016/j.it.2005.11.005_bib7 article-title: Interleukin-12 and the regulation of innate resistance and adaptive immunity publication-title: Nat. Rev. Immunol. doi: 10.1038/nri1001 – volume: 26 start-page: 273 year: 2005 ident: 10.1016/j.it.2005.11.005_bib12 article-title: Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances publication-title: Springer Semin. Immunopathol. doi: 10.1007/s00281-004-0168-0 – volume: 19 start-page: 877 year: 2003 ident: 10.1016/j.it.2005.11.005_bib37 article-title: CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells publication-title: Immunity doi: 10.1016/S1074-7613(03)00327-3 – volume: 17 start-page: 275 year: 2005 ident: 10.1016/j.it.2005.11.005_bib21 article-title: CD27 and CD70 in T cell and B cell activation publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2005.04.004 – volume: 21 start-page: 961 year: 2003 ident: 10.1016/j.it.2005.11.005_bib74 article-title: Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice publication-title: Vaccine doi: 10.1016/S0264-410X(02)00737-5 – volume: 433 start-page: 887 year: 2005 ident: 10.1016/j.it.2005.11.005_bib23 article-title: Toll-like receptor 3 promotes cross-priming to virus-infected cells publication-title: Nature doi: 10.1038/nature03326 – volume: 172 start-page: 1501 year: 2004 ident: 10.1016/j.it.2005.11.005_bib24 article-title: CpG-DNA aided cross-priming by cross-presenting B cells publication-title: J. Immunol. doi: 10.4049/jimmunol.172.3.1501 – volume: 5 start-page: 987 year: 2004 ident: 10.1016/j.it.2005.11.005_bib3 article-title: Toll-like receptor control of the adaptive immune responses publication-title: Nat. Immunol. doi: 10.1038/ni1112 – volume: 149 start-page: 53 issue: Suppl. 66 year: 2003 ident: 10.1016/j.it.2005.11.005_bib68 article-title: The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview publication-title: Br. J. Dermatol. doi: 10.1046/j.0366-077X.2003.05626.x – volume: 168 start-page: 1533 year: 2002 ident: 10.1016/j.it.2005.11.005_bib51 article-title: Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent publication-title: J. Immunol. doi: 10.4049/jimmunol.168.4.1533 – volume: 339 start-page: 209 year: 1998 ident: 10.1016/j.it.2005.11.005_bib40 article-title: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199807233390401 – volume: 71 start-page: 5590 year: 2003 ident: 10.1016/j.it.2005.11.005_bib52 article-title: Activation of human dendritic cells is modulated by components of the outer membranes of Neisseria meningitidis publication-title: Infect. Immun. doi: 10.1128/IAI.71.10.5590-5597.2003 – volume: 8 start-page: 389 year: 2001 ident: 10.1016/j.it.2005.11.005_bib66 article-title: CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer publication-title: Ann. Surg. Oncol. doi: 10.1007/s10434-001-0389-6 – volume: 167 start-page: 987 year: 2001 ident: 10.1016/j.it.2005.11.005_bib41 article-title: Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling publication-title: J. Immunol. doi: 10.4049/jimmunol.167.2.987 – volume: 191 start-page: 654 year: 2005 ident: 10.1016/j.it.2005.11.005_bib56 article-title: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection publication-title: J. Infect. Dis. doi: 10.1086/428404 – volume: 23 start-page: 1258 year: 2005 ident: 10.1016/j.it.2005.11.005_bib29 article-title: TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2004.09.001 – volume: 203 start-page: 10 year: 2005 ident: 10.1016/j.it.2005.11.005_bib39 article-title: Inherited disorders of human Toll-like receptor signaling: immunological implications publication-title: Immunol. Rev. doi: 10.1111/j.0105-2896.2005.00235.x – volume: 170 start-page: 4102 year: 2003 ident: 10.1016/j.it.2005.11.005_bib25 article-title: A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells publication-title: J. Immunol. doi: 10.4049/jimmunol.170.8.4102 – volume: 163 start-page: 3920 year: 1999 ident: 10.1016/j.it.2005.11.005_bib48 article-title: Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis publication-title: J. Immunol. doi: 10.4049/jimmunol.163.7.3920 – volume: 171 start-page: 5611 year: 2003 ident: 10.1016/j.it.2005.11.005_bib55 article-title: Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1 publication-title: J. Immunol. doi: 10.4049/jimmunol.171.10.5611 – volume: 298 start-page: 1025 year: 2002 ident: 10.1016/j.it.2005.11.005_bib73 article-title: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2 publication-title: Science doi: 10.1126/science.1075565 – volume: 2 start-page: 947 year: 2001 ident: 10.1016/j.it.2005.11.005_bib72 article-title: Toll-like receptors control activation of adaptive immune responses publication-title: Nat. Immunol. doi: 10.1038/ni712 – volume: 64 start-page: 409 year: 2004 ident: 10.1016/j.it.2005.11.005_bib69 article-title: Current and new strategies in immunotherapy for superficial bladder cancer publication-title: Urology doi: 10.1016/j.urology.2004.04.026 – volume: 12 start-page: 129 year: 2005 ident: 10.1016/j.it.2005.11.005_bib13 article-title: Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction publication-title: Gene Ther. doi: 10.1038/sj.gt.3302358 – volume: 309 start-page: 1380 year: 2005 ident: 10.1016/j.it.2005.11.005_bib38 article-title: Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function publication-title: Science doi: 10.1126/science.1113401 – volume: 9 start-page: 3142 year: 2003 ident: 10.1016/j.it.2005.11.005_bib59 article-title: Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides publication-title: Clin. Cancer Res. – volume: 25 start-page: 381 year: 2004 ident: 10.1016/j.it.2005.11.005_bib30 article-title: The immunobiology of the TLR9 subfamily publication-title: Trends Immunol. doi: 10.1016/j.it.2004.04.011 – volume: 22 start-page: 1782 year: 2004 ident: 10.1016/j.it.2005.11.005_bib77 article-title: Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model publication-title: Vaccine doi: 10.1016/j.vaccine.2004.01.037 – volume: 199 start-page: 201 year: 2004 ident: 10.1016/j.it.2005.11.005_bib26 article-title: Use of CpG oligodeoxynucleotides as immune adjuvants publication-title: Immunol. Rev. doi: 10.1111/j.0105-2896.2004.00148.x – volume: 172 start-page: 1347 year: 2004 ident: 10.1016/j.it.2005.11.005_bib19 article-title: Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production publication-title: J. Immunol. doi: 10.4049/jimmunol.172.3.1347 – volume: 416 start-page: 603 year: 2002 ident: 10.1016/j.it.2005.11.005_bib31 article-title: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors publication-title: Nature doi: 10.1038/416603a – volume: 4 start-page: 1223 year: 2003 ident: 10.1016/j.it.2005.11.005_bib17 article-title: Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways publication-title: Nat. Immunol. doi: 10.1038/ni1010 – volume: 8 start-page: 509 year: 2000 ident: 10.1016/j.it.2005.11.005_bib58 article-title: Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism publication-title: Nat. Biotechnol. doi: 10.1038/75365 |
| SSID | ssj0015777 ssj0013055 |
| Score | 2.354558 |
| SecondaryResourceType | review_article |
| Snippet | Toll-like receptors (TLRs) are a family of pattern-recognition receptors that are an important link between innate and adaptive immunity. Many established, as... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 49 |
| SubjectTerms | Animals Cell Movement Dendritic Cells - cytology Dendritic Cells - immunology Humans Immune Tolerance - immunology Signal Transduction - immunology Toll-Like Receptors - immunology Vaccination |
| Title | Triggering TLR signaling in vaccination |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1471490605002863 https://dx.doi.org/10.1016/j.it.2005.11.005 https://www.ncbi.nlm.nih.gov/pubmed/16310411 https://www.proquest.com/docview/17084801 https://www.proquest.com/docview/70692017 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB7URfEivl0faw-CeKjbtGnSHpdVWR_rQVfwVtIklYpU0Sp48bc7adNdBB_gqbTMQJpJJjOZxwewl4qAyUxFbsqCzKVpxt3Yj0KX6Fhwqpjm1BQKDy_Z4Iae3Ya3U9BvamFMWqXV_bVOr7S1_dK1s9l9yvPuNUG9SmMP7XHjOLBgGlp-EDNc2q3e6fngchxMCHkFwGjoXcNgo5V1mlde1hcrppWnwbD7_nT6yfqsTqGTRViw5qPTq0e4BFO6WIbZGlDyfRnmhjZUvgL7I_S776pGg87o4soxiRrC1J47eeG8CYlUlVBW4ebkeNQfuBYVwZXoKpQu-kdUcEk1UQJ9D8H8LOWKeVnkcy5k5kci8rXSgnImzA0PVWnk6UBJT-CBRYM1mCkeC70BDu5owRRFXqloIFE8KcvSKIpD9Bu00G3oNrORSNsy3CBXPCRNbth9kpcGyTJETyLBRxsOxhxPdbuMX2hJM8FJUwaKiitBXf4LTzDm-bJM_uDabeSX4O4xIRFR6MfXl4RwgyfgkZ8puMdiNJJ4G9ZrwU_-i6FpTAnZ_NeYtmB-cpuzDTPl86veQfumTDswffhBOnYV49vR6fknrHP3MQ |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB584OMivl2fPQjiobZp06Q9iiir7nrQFbyFNEmlIt1Fq-DF3-6kjxXBB3gqhBlIM5nJTDIzH8B-KkOmMh27KQszl6YZd5MgjlxiEsmpZoZTWyjcv2LdW3pxF91NwElbC2PTKhvbX9v0ylo3I16zmt4oz70bgnaVJj764zZwYOEkTFNUX6udR-_jPA8S8Qp-0VK7lrx5q6yTvPKyvlaxjTwtgt33Z9NPvmd1Bp0twkLjPDrH9fyWYMIUyzBTw0m-LcNsv3koX4GDAUbd91WbQWfQu3Zsmoa0ledOXjivUiFVJZJVuD07HZx03QYTwVUYKJQuRkdUckUN0RIjD8mCLOWa-VkccC5VFsQyDow2knIm7f0O1Wnsm1ArX-JxRcM1mCqGhdkAB_VZMk2RV2kaKhROyrI0jpMIowYjTQe8djWEahqGW9yKR9Fmhj2IvLQ4lhHGEQI_HTgcc4zqZhm_0JJ2gUVbBIpmS6Al_4UnHPN82SR_cO218hOoO_ZBRBZm-PIsCLdoAj75mYL7LEEXiXdgvRb8538xdIwpIZv_mtMezHUH_Z7onV9dbsH8573ONkyVTy9mBz2dMt2tdvIH3vX2_A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Triggering+TLR+signaling+in+vaccination&rft.jtitle=Trends+in+immunology&rft.au=van+Duin%2C+David&rft.au=Medzhitov%2C+Ruslan&rft.au=Shaw%2C+Albert+C.&rft.date=2006&rft.pub=Elsevier+Ltd&rft.issn=1471-4906&rft.eissn=1471-4981&rft.volume=27&rft.issue=1&rft.spage=49&rft.epage=55&rft_id=info:doi/10.1016%2Fj.it.2005.11.005&rft.externalDocID=S1471490605002863 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-4906&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-4906&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-4906&client=summon |